Novo Nordisk Short Term Debt Over Time
| NVO Stock | USD 109.19 1.89 1.70% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Novo Nordisk Performance and Novo Nordisk Correlation. Novo |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Term Debt Analysis
Compare Novo Nordisk AS and related stocks such as Regeneron Pharmaceuticals, Crispr Therapeutics, and Sarepta Therapeutics Short Term Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | 400 K | 1 M | 1.4 M | 939 K | 350.2 M | 452.6 M | 127.3 M | 468.8 M | 90.8 M | 1.6 B | 1.6 B | 1.4 B | 720 M | 828 M | 869.4 M |
| CRSP | 38 M | 38 M | 38 M | 38 M | 38 M | 38.3 M | 60.3 M | 44.2 M | 35.3 M | 8.5 M | 22.7 M | 24.3 M | 31.7 M | 31.2 M | 26.8 M |
| SRPT | 71.1 K | 85 K | 89 K | 92 K | 2.6 M | 8.4 M | 10.1 M | 6.2 M | 134.1 M | 7.8 M | 193.6 M | 271.7 M | 15.5 M | 141.2 M | 148.2 M |
| NTLA | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 11.4 M | 18.2 M | 16.7 M | 37.2 M | 19.6 M |
| MRNA | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 72.7 M | 79.1 M | 67.7 M | 30 M | 1.1 B | 244 M | 25 M | 23.8 M |
| CVAC | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 2 M | 3.2 M | 3.5 M | 5 M | 5 M | 3.5 M |
| NVAX | 100 K | 20 K | 215 K | 985 K | 603 K | 395 K | 29.6 M | 34.7 M | 24.6 M | 1.3 M | 322 M | 130.5 M | 352.1 M | 5.1 M | 4.9 M |
| BNTX | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 19.4 M | 6.2 M | 7.6 M | 15.2 M | 129.9 M | 36 M | 56.2 M | 37.6 M |
| DNA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 485 K | 747 K | 29.3 M | 19.9 M | 11.1 M |
| VRTX | 800 K | 195.4 M | 13.7 M | 16.9 M | 32 M | 87 M | 319.4 M | 22.5 M | 9.8 M | 30.3 M | (275 M) | 80.2 M | 89.4 M | 83.7 M | 87.9 M |
| BMRN | 26 K | 23.4 M | 23.4 M | 642.9 M | 642.9 M | 662.3 M | 22.5 M | 360.9 M | 361.9 M | 361.9 M | 11.8 M | 10.5 M | 10.4 M | 502.7 M | 527.8 M |
| ALNY | 558 K | 62.9 M | 4.2 M | 2.9 M | 5 M | 6.7 M | 11.5 M | 11 M | 62.9 M | 303.8 M | 50.2 M | 77.6 M | 82.3 M | 96.5 M | 101.3 M |
| MDGL | 537 K | 4.2 M | 7.9 M | 9.5 M | 9.3 M | 4.7 M | 315 K | 315 K | 315 K | 315 K | 636 K | 820 K | 602 K | 1.1 M | 1 M |
| TGTX | 70 K | 877.8 K | 677.8 K | 677.8 K | 275.2 K | 211.5 K | 68.9 K | 127.6 K | 67 K | 1.6 M | 23.8 M | 3.8 M | 3.2 M | 1.4 M | 2.8 M |
| TERN | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 1.3 M | 1.3 M | 1.2 M | 1.1 M |
| HEPA | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 1.4 M | 1.4 M | 266.7 K | 559.7 K | 533.3 K | 107.2 K | 231.8 K | 359.9 K |
Novo Nordisk AS and related stocks such as Regeneron Pharmaceuticals, Crispr Therapeutics, and Sarepta Therapeutics Short Term Debt description
My Equities
My Current Equities and Potential Positions
| Novo Nordisk AS | NVO |
| Classification | Baby Boomer Prospects |
| Location | Denmark |
| Exchange | New York Stock Exchange |
USD 109.19
Check out Novo Nordisk Performance and Novo Nordisk Correlation. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Novo Nordisk technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.